Showing 1 - 20 results of 21 for search 'Eunice S. Wang', query time: 0.07s
Refine Results
-
1
Acute leukemia with KMT2A rearrangement: A master of disguise by Sawyer J. Bawek, Eunice S. Wang, Steven D. Green
Published 2024-01-01
Article -
2
-
3
-
4
-
5
High pseudotumor cerebri incidence in tretinoin and arsenic treated acute promyelocytic leukemia and the role of topiramate after acetazolamide failure by Morgan B. Smith, Elizabeth A. Griffiths, James E. Thompson, Eunice S. Wang, Meir Wetzler, Craig W. Freyer
Published 2014-01-01
Article -
6
Predictors of vascular disease in myelodysplastic syndromes by Mark G. Faber, David R. Lloyd, Abhay Singh, Jeffrey Baron, Amanda Przespolewski, Elizabeth A. Griffiths, Eunice S. Wang, Swapna Thota
Published 2020-11-01
Article -
7
-
8
Emerging trends of therapy related myeloid neoplasms following modern cancer therapeutics in the United States by Abhay Singh, Megan M. Herr, Elizabeth A. Griffiths, Amanda Przespolewski, Mark G. Faber, Chebli Mrad, Eunice S. Wang, Theresa Hahn, Swapna Thota
Published 2021-12-01
Article -
9
-
10
Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia by Jorge E. Cortes, Marcos de Lima, Hervé Dombret, Elihu H. Estey, Sergio A. Giralt, Pau Montesinos, Christoph Röllig, Adriano Venditti, Eunice S. Wang
Published 2020-10-01
Article -
11
Mitochondrial hypoxic stress induces widespread RNA editing by APOBEC3G in natural killer cells by Shraddha Sharma, Jianmin Wang, Emad Alqassim, Scott Portwood, Eduardo Cortes Gomez, Orla Maguire, Per H. Basse, Eunice S. Wang, Brahm H. Segal, Bora E. Baysal
Published 2019-02-01
Article -
12
Pharmacological targeting of β-catenin in normal karyotype acute myeloid leukemia blasts by Elizabeth A. Griffiths, Michelle C. Golding, Pragya Srivastava, Benjamin J. Povinelli, Smitha R. James, Laurie A. Ford, Meir Wetzler, Eunice S. Wang, Michael J. Nemeth
Published 2015-02-01
Article -
13
Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia by Harry P. Erba, Pamela S. Becker, Paul J. Shami, Michael R. Grunwald, Donna L. Flesher, Min Zhu, Erik Rasmussen, Haby A. Henary, Abraham A. Anderson, Eunice S. Wang
Published 2019-07-01
Article -
14
Phase 1 dose escalation study of the MDM2 inhibitor milademetan as monotherapy and in combination with azacitidine in patients with myeloid malignancies by Courtney D. DiNardo, Rebecca Olin, Eunice S. Wang, Barry Skikne, Joseph Rosenthal, Prasanna Kumar, Hiroyuki Sumi, Yoshiyuki Hizukuri, Ying Hong, Parul Patel, Takahiko Seki, Tao Duan, Arnaud Lesegretain, Michael Andreeff
Published 2024-07-01
Article -
15
Gemtuzumab ozogamicin plus standard induction chemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemia by Hassan Awada, Mina Abdelmalek, Tara Cronin, Jeffrey Baron, Zakariya Kashour, Farhan Azad, Muhammad Salman Faisal, Mark Faber, Matthew Gravina, Pamela J. Sung, Steven D. Green, Amanda Przespolewski, James E. Thompson, Elizabeth A. Griffiths, Eunice S. Wang
Published 2023-09-01
Article -
16
Small molecule MMRi62 targets MDM4 for degradation and induces leukemic cell apoptosis regardless of p53 status by Rati Lama, Chao Xu, Samuel L. Galster, Javier Querol-García, Scott Portwood, Cory K. Mavis, Federico M. Ruiz, Diana Martin, Jin Wu, Marianna C. Giorgi, Jill Bargonetti, Eunice S. Wang, Francisco J. Hernandez-Ilizaliturri, Gerald B. Koudelka, Sherry R. Chemler, Inés G. Muñoz, Xinjiang Wang
Published 2022-08-01
Article -
17
Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phas... by Jorge E. Cortes, Gail J. Roboz, Maria R. Baer, Brian A. Jonas, Gary J. Schiller, Karen Yee, P. Brent Ferrell, Jay Yang, Eunice S. Wang, William G. Blum, Alice Mims, Hua Tian, Aaron Sheppard, Stéphane de Botton, Pau Montesinos, Antonio Curti, Justin M. Watts, the Olutasidenib Combination Therapy Study Group
Published 2025-01-01
Article -
18
A precision medicine classification for treatment of acute myeloid leukemia in older patients by Alice S. Mims, Jessica Kohlschmidt, Uma Borate, James S. Blachly, Shelley Orwick, Ann-Kathrin Eisfeld, Dimitrios Papaioannou, Deedra Nicolet, Krzysztof Mrόzek, Eytan Stein, Bhavana Bhatnagar, Richard M. Stone, Jonathan E. Kolitz, Eunice S. Wang, Bayard L. Powell, Amy Burd, Ross L. Levine, Brian J. Druker, Clara D. Bloomfield, John C. Byrd
Published 2021-06-01
Article -
19
Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia by Dimitrios Papaioannou, Deedra Nicolet, Stefano Volinia, Krzysztof Mrózek, Pearlly Yan, Ralf Bundschuh, Andrew J. Carroll, Jessica Kohlschmidt, William Blum, Bayard L. Powell, Geoffrey L. Uy, Jonathan E. Kolitz, Eunice S. Wang, Ann-Kathrin Eisfeld, Shelley J. Orwick, David M. Lucas, Michael A. Caligiuri, Richard M. Stone, John C. Byrd, Ramiro Garzon, Clara D. Bloomfield
Published 2017-08-01
Article -
20
A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia by Joshua F. Zeidner, Tara L. Lin, Carlos E. Vigil, Gil Fine, M. Yair Levy, Aziz Nazha, Jordi Esteve, Daniel J. Lee, Karen Yee, Andrew Dalovisio, Eunice S. Wang, Juan M. Bergua Burgues, Jeffrey Schriber, Mark R. Litzow, Olga Frankfurt, Teresa Bernal Del Castillo, Vijaya Raj Bhatt, Bhavana Bhatnagar, Priyanka Mehta, Richard Dillon, Maria Vidriales Vicente, Stephen Anthony, David Bearss, Pau Montesinos, B. Douglas Smith
Published 2021-10-01
Article